bluebird bio Announces September Investor Events
August 28 2024 - 8:00AM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced that
members of the management team will participate in fireside chats
at the following upcoming investor conferences:
- 2024 Wells Fargo Healthcare Conference, Wednesday, September 4,
at 12:45 p.m. ET at the Encore Boston Harbor, Everett, MA
- Morgan Stanley 22nd Annual Global Healthcare Conference,
Thursday, September 5, at 5:35 p.m. ET at the New York Marriott
Marquis, New York, NY
To access the live webcast of bluebird bio’s fireside chats,
please visit the “Events & Presentations” page within the
Investors & Media section of the bluebird bio website at
http://investor.bluebirdbio.com. Replays of the webcasts will be
available on the bluebird bio website for 90 days following the
events.
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give
patients and their families more bluebird days.
Founded in 2010, bluebird has been setting the standard for gene
therapy for more than a decade—first as a scientific pioneer and
now as a commercial leader. bluebird has an unrivaled track record
in bringing the promise of gene therapy out of clinical studies and
into the real-world setting, having secured FDA approvals for three
therapies in under two years. Today, we are proving and scaling the
commercial model for gene therapy and delivering innovative
solutions for access to patients, providers, and payers.
With a dedicated focus on severe genetic diseases, bluebird has
the largest and deepest ex-vivo gene therapy data set in the field,
with industry-leading programs for sickle cell disease,
β-thalassemia and cerebral adrenoleukodystrophy. We custom design
each of our therapies to address the underlying cause of disease
and have developed in-depth and effective analytical methods to
understand the safety of our lentiviral vector technologies and
drive the field of gene therapy forward.
bluebird continues to forge new paths as a standalone commercial
gene therapy company, combining our real-world experience with a
deep commitment to patient communities and a people-centric culture
that attracts and grows a diverse flock of dedicated birds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240828846235/en/
Investors: Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com
Media: Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Aug 2024 to Sep 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Sep 2023 to Sep 2024